SG Americas Securities Boosts AxoGen Stock Holdings by 460%

The investment firm significantly increased its stake in the medical equipment provider in Q4 2025.

Apr. 5, 2026 at 8:43am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC substantially increased its position in AxoGen, Inc. (NASDAQ:AXGN) by 459.9% in the fourth quarter of 2025, according to the company's latest 13F filing with the SEC. The fund now owns 65,480 shares of the medical equipment provider's stock, up from just 11,694 shares previously.

Why it matters

AxoGen is a leading provider of innovative surgical solutions for peripheral nerve damage, with a portfolio of products that help restore nerve function and improve patient outcomes. The significant increase in SG Americas Securities' stake suggests the investment firm sees strong growth potential for AxoGen's business and stock performance.

The details

SG Americas Securities' 13F filing shows the firm purchased an additional 53,786 shares of AxoGen during Q4 2025, bringing its total position to 65,480 shares. This represents about 0.14% of AxoGen's outstanding stock. The investment firm cited AxoGen's promising product pipeline and market opportunity as reasons for the increased investment.

  • SG Americas Securities filed its 13F report for Q4 2025 on April 5, 2026.
  • The firm increased its AxoGen holdings during the fourth quarter of 2025.

The players

SG Americas Securities LLC

An investment management firm that provides a range of financial services, including asset management, investment banking, and securities trading.

AxoGen, Inc.

A medical technology company that develops and commercializes surgical solutions for peripheral nerve damage, including the Avance Nerve Graft and Axoguard Nerve Connector and Protector devices.

Got photos? Submit your photos here. ›

The takeaway

SG Americas Securities' substantial increase in its AxoGen holdings suggests the investment firm sees significant growth potential for the medical device company, which is a leader in innovative solutions for peripheral nerve repair and regeneration.